Phio Pharmaceuticals completes commercial-scale batch
- Completed first commercial-scale cGMP batch of PH-762 drug substance
- Phase 2b trial planned for Q1 2027
- Manufacturing compliant with cGMP regulations
Every EDGAR filing for Phio Pharmaceuticals Corp. (PHIO), newest first, with AI summaries and stories.
Next: earnings expected ~Nov 16 · 10-Q expected ~Nov 16 (deadline Nov 16)
Also: 3 grants or exercises.
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
Ronald Todd Plott, insider filing for PHIO
Ronald Todd Plott, reporting
Ronald Todd Plott, insider filing for PHIO
Ronald Todd Plott, reporting
Patricia A Bradford, insider filing for PHIO
Patricia A Bradford, reporting
Robert J Bitterman, insider filing for PHIO
Robert J Bitterman, reporting
Patricia A Bradford, insider filing for PHIO
Patricia A Bradford, reporting
Robert J Bitterman, insider filing for PHIO
Robert J Bitterman, reporting
Ronald Todd Plott, insider filing for PHIO
Ronald Todd Plott, reporting
Robert J Bitterman, insider filing for PHIO
Robert J Bitterman, reporting
Ronald Todd Plott, new insider at PHIO
Ronald Todd Plott, reporting
Robert J Bitterman, insider filing for PHIO
Robert J Bitterman, reporting
Ownership stake disclosure by CVI Investments, Inc. (amended)
CVI Investments, Inc., filed by
Ownership stake disclosure by INTRACOASTAL CAPITAL, LLC (amended)
INTRACOASTAL CAPITAL, LLC, filed by
Curtis Lockshin, insider filing for PHIO
Curtis Lockshin, reporting
Robert J Bitterman, insider filing for PHIO
Robert J Bitterman, reporting
Robert J Bitterman, insider filing for PHIO
Robert J Bitterman, reporting
Ownership stake disclosure by Orca Capital AG (amended)
Orca Capital AG, filed by
Orca Capital AG, filed by
Robert J Bitterman, reporting